As for those RA patients who switched to another TNF-α antagonist or received a second-line biologic agent, they had more outpatient visits, stayed in hospitals longer, and consumed more emergency room services during the 1-year follow-up. The gene discussed is TNF; the disease is rheumatoid arthritis.